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Abstract In this report, we deal with the isolation of a novel
vasorelaxing peptide from a chymotryptic digest of ovalbumin
and its vasorelaxing activities. This peptide is composed of Arg-
Ala-Asp-His-Pro-Phe (RADHPF) in its sequence, corresponding
to residues 359^364 of ovalbumin. This peptide (30^300 WM)
exerted a dose-dependent vasodilation in an isolated mesenteric
artery from a spontaneously hypertensive rat which was pre-
constricted by phenylephrine, besides the relaxation being
endothelium-dependent. It is noteworthy that the nitric oxide
synthase inhibitor NG-nitro-L-arginine methyl ester inhibited this
relaxation, implying involvement of nitric oxide in its mechanism
of action. Following oral administration of RADHPF at a dose
of 10 mg/kg, the systolic blood pressure in a spontaneously
hypertensive rat was significantly lowered.
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Many kinds of biologically active peptides including opioid
peptides and inhibitory peptides for angiotensin I-converting
enzymes have been isolated from enzymatic digests of various
food proteins [1^4].
In the previous study, we reported that ovokinin, an octa-
peptide with vasorelaxing activity in an isolated canine mes-
enteric artery, was obtained from the peptic digest of ovalbu-
min [5]. Onset of this relaxation was partly dependent on
endothelium and attributable to the activation of bradykinin
B1 receptors. Moreover, the endothelium-dependent relaxing
factor involved therein was identi¢ed as prostaglandin I2 but
not nitric oxide (NO).
In sharp contrast, however, the present study revealed that
the novel peptide isolated from the chymotryptic digest of
ovalbumin showed completely endothelium-dependent vasore-
laxation in an isolated spontaneously hypertensive rat (SHR)
mesenteric artery and the relaxing factor was evidenced to be
NO.
2. Materials and methods
2.1. Chemicals and reagents
Ovalbumin (grade VI), bovine K-chymotrypsin (TLCK-treated, type
VII) and indomethacin were purchased from Sigma Chemical. NG-
nitro-L-arginine methyl ester (L-NAME) was purchased from Nacalai
Tesque. Phenylephrine hydrochloride was obtained from Research
Biochemicals, papaverine hydrochloride from Daiichi Seiyaku, des-
Arg9-(Leu8)-bradykinin, HOE140 and charybdotoxin from Peptide
Institute and apamin from American Peptide Company.
2.2. Chymotryptic digestion of ovalbumin
Ovalbumin (25 mg/ml) was adjusted to pH 7.8 with 0.5 N NaOH
and digested two times by chymotrypsin (E/S = 1/100 (weight/weight))
for 12 h each at 37‡C. The reaction was stopped by boiling for 10 min
and then, the reaction mixture was centrifuged.
2.3. Puri¢cation of peptides
The digest was fractionated by reversed phase high performance
liquid chromatography (HPLC) on an octadecyl silica (ODS) column
(Cosmosil 5C18-AR, 20U250 mm, Nacalai Tesque). The column was
eluted with a linear gradient of acetonitrile (1%/min), containing 0.1%
tri£uoroacetic acid (TFA) at a £ow rate of 10 ml/min. The elution was
monitored at 215 nm. Each fraction was dried with a centrifugal
concentrator and vasorelaxing activity was measured in an isolated
SHR mesenteric artery. The active fraction was further puri¢ed by a
phenethyl silica column (Develosil PhA-T-5, 4.6U250 mm) developed
by the same linear gradient of acetonitrile as described above at a £ow
rate of 1 ml/min.
2.4. Amino acid sequence analysis and peptide synthesis
The amino acid sequence of the puri¢ed peptide was determined by
a 492 protein sequencer (Applied Biosystems), whereby PS3 (Rainin)
peptide synthesizers were used to synthesize the peptide.
2.5. Vasorelaxation assay
Male SHRs (15^29 weeks old) and age-matched normotensive Wis-
tar-Kyoto rats (WKYs) were exsanguinated from the common carotid
artery under sodium pentobarbital anesthesia (25 mg/kg, intraperito-
neal (i.p.)). The mesenteric arteries were then removed and cut into
ring strips. The endothelium was removed mechanically by gently
rubbing the intimal surface. The absence of functional endothelium
was con¢rmed by the inability of acetylcholine to induce relaxation.
Intact and endothelium-denuded arteries were mounted between two
stainless steel hooks in an organ bath containing a Krebs-Henseleit
solution (120 mM NaCl, 4.7 mM KCl, 1.2 mM MgSO4, 1.2 mM
KH2PO4, 2.5 mM CaCl2, 25 mM NaHCO3 and 10 mM glucose) at
37‡C and bubbled with a mixture of 95% 02/5% CO2. The end of the
hook was attached to the lever of a force-displacement transducer
(T7-8-240, Orientec), which was connected to a Recti-Horiz-8K re-
corder (NEC San-ei Instrument), thereby recording the isometric ten-
sion changes. The applied tension was adjusted to 1 g, followed by a
3 h equilibration period. The artery was constricted by phenylephrine
(1037^1036 M). The relaxing activity of samples was assayed in the
presence or absence of inhibitors or antagonists applied 15 min before
the addition of phenylephrine. To determine the complete relaxation
point, 1034 M papaverine was added at the end of each examination.
2.6. Measurement of the blood pressure
Male SHRs (15^29 weeks old) and age-matched normotensive
WKYs were used. The peptide emulsi¢ed with 30% egg yolk in saline
was administered orally in SHRs using a metal zonde in a volume of
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0.5 ml. Following oral administration of the peptide, the blood pres-
sure was measured by the tail cu¡ method using a UR-5000 (Ueda
Seisakusho) to ascertain its anti-hypertensive activity, while only egg
yolk was administered as a control.
2.7. Data analyses
All results are expressed as means and S.E.M. Comparisons of the
results between the two groups were statistically made with Student’s
t-test.
3. Results
3.1. Isolation of the vasorelaxing peptide from the chymotryptic
digest of ovalbumin
It was disclosed that the chymotryptic digest of ovalbumin
exerted a vasorelaxing activity in an isolated SHR mesenteric
artery. As shown in Fig. 1A, the chymotryptic digest relaxed a
SHR mesenteric artery which was pre-constricted by phenyl-
ephrine. In order to isolate the vasorelaxing peptide, the digest
was fractionated by reversed phase HPLC on an ODS col-
umn. Among all the fractions measured, two active peaks
were eluted at about 25 and 28% of acetonitrile (Fig. 2A).
The former peak showed a higher vasorelaxing activity than
the latter one. Consequently, our research has focused on the
former in this report. For further puri¢cation, fractionation of
the active peak was conducted on a phenethyl silica column,
allowing isolation of an active peptide in a pure form (Fig.
2B). The structure of this peptide, determined by a protein
sequencer, was Arg-Ala-Asp-His-Pro-Phe, being consistent
with residues 359^364 of ovalbumin. Furthermore, this pep-
tide was identical to the 2-7 fragment of ovokinin
(FRADHPFL). Incidentally, ovokinin was previously isolated
in our laboratory as a vasorelaxing peptide acting via the
bradykinin B1 receptors in an isolated canine mesenteric ar-
tery [5]. Although neither ovokinin (1034 M) nor endogenous
B1 agonist des-Arg9-bradykinin (1037 M) exhibited a signi¢-
cant vasorelaxing activity in an isolated SHR mesenteric ar-
tery (data not shown), a synthetic 2-7 fragment of ovokinin
(ovokinin(2-7)) showed a potent vasodilation at 1034 M in the
same artery specimens (Fig. 1B).
3.2. Relaxation mechanism of ovokinin(2-7)
As shown in Fig. 3A, ovokinin(2-7) induced a dose-depend-
ent relaxation in a SHR mesenteric artery. The percentage of
dilation of the phenylephrine-constricted mesenteric artery by
1034 M ovokinin(2-7) accounted for 67.5%, with the relaxa-
tion saturated at 3U1034 M. On the other hand, the vaso-
relaxation in a WKY mesenteric artery was signi¢cantly
smaller than that in SHR’s. As shown in Fig. 3B, ovoki-
nin(2-7)-induced vasorelaxation was endothelium-dependent.
To discern the features characteristic of this new endothe-
lium-dependent relaxing factor, investigations were performed
on the e¡ect of inhibitors of NO synthase (L-NAME), cyclo-
oxygenase (indomethacin) and Ca2-activated K channels
(apamin plus charybdotoxin) on the ovokinin(2-7)-induced
vasorelaxation. As illustrated in Fig. 3B, L-NAME inhibited
the relaxation, whereas indomethacin failed to show any in-
teraction. Although the combination of apamin plus charyb-
dotoxin slightly attenuated the relaxation (20.9%), the inhib-
itory e¡ect was not signi¢cant (P = 0.085). In addition, neither
des-Arg9-(Leu8)-bradykinin (B1 antagonist) nor HOE140 (B2
antagonist) were found to be e¡ective.
Fig. 1. Vasorelaxing activity of a chymotryptic digest of ovalbumin
(A) and ovokinin(2-7) (B) in an isolated SHR mesenteric artery.
phenyl.: phenylephrine. papav.: 1034 M papaverine.
Fig. 2. Puri¢cation of vasorelaxing peptides from the chymotryptic
digest of ovalbumin by reversed phase HPLC on an ODS column
(A) and further puri¢cation of peak (a) on a phenethyl silica col-
umn (B). Active fractions are indicated by arrows.
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3.3. Anti-hypertensive activity of ovokinin(2-7) after oral
administration in SHRs
Vasorelaxing activity of ovokinin(2-7) in the isolated mes-
enteric artery specimen prompted our investigation on the
hypotensive e¡ect after its oral administration to SHR. Given
the fact that the e¡ect of various anti-hypertensive peptides
was potentiated by emulsi¢cation in 30% egg yolk [6,7], we
orally administered ovokinin(2-7) emulsi¢ed in 30% egg yolk
to SHRs. As is obvious in Fig. 4A, 2 h after the administra-
tion of ovokinin(2-7) at a dose of 20 mg/kg, the systolic blood
pressure of SHRs started to decrease, with the signi¢cant ef-
fect observed 4 and 6 h post-administration. The maximal
e¡ect was dose-dependently noted 6 h after administration
(Fig. 4B). On the other hand, ovokinin(2-7) at a dose of 20
mg/kg did not show any signi¢cant hypotensive e¡ect in
WKYs (Fig. 4B).
4. Discussion
In this study, we isolated a novel vasorelaxing peptide,
ovokinin(2-7), from a chymotryptic digest of ovalbumin
and con¢rmed its vasorelaxing e¡ect by using an isolated
SHR mesenteric artery. Our view is that this assay system
seems to be useful for the screening of new vasorelaxing pep-
tides.
Ovokinin(2-7) showed a dose-dependent relaxation in an
isolated SHR mesenteric artery. However, removal of the en-
dothelium was associated with disappearance of the relaxation
e¡ect, demonstrating that this relaxation is endothelium-de-
pendent. Moreover, the dilation was inhibited by L-NAME
but not by indomethacin, indicating implication of the NO
release from the endothelial cells upon onset of the vasorelax-
ation. Although the relaxation was slightly attenuated in the
presence of apamin plus charybdotoxin, the inhibitory e¡ect
was not signi¢cant, suggesting that endothelium-derived hy-
perpolarizing factor (EDHF) does not play an essential role in
the relaxation.
It is well known that production of the superoxide anion
(O32 ), which inactivates NO, is increased in the vessel of SHRs
[8,9]. Nevertheless, pretreatment of superoxide dismutase (150
U/ml) did not blunt the ovokinin(2-7)-induced vasorelaxation
in a SHR mesenteric artery (data not shown), suggesting that
this relaxation is not caused by scavenging O32 but by stim-
ulating the NO production.
Taken together, it is postulated that ovokinin(2-7) might act
on receptors of some endogenous vasoactive peptide condu-
Fig. 3. (A) Dose-dependent vasorelaxing activity of ovokinin(2-7) in the mesenteric artery of SHRs and WKYs. (B) The e¡ect of endothelium
removal and various inhibitors on ovokinin(2-7)-induced vasorelaxation. Control: 1034 M ovokinin(2-7). ChTX: charybdotoxin. B1 antagonist:
des-Arg9-(Leu8)-bradykinin. B2 antagonist: HOE140. Each value is expressed as mean þ S.E.M. Parentheses represent the number of experi-
ments. **, ***: Signi¢cant di¡erence against the parallel control (**P6 0.01, ***P6 0.001).
Fig. 4. (A) Time course of ovokinin(2-7)-induced anti-hypertensive activity (20 mg/kg) after oral administration in SHRs. (B) Dose-dependent
anti-hypertensive e¡ect of ovokinin(2-7) 6 h after administration. Changes in the systolic blood pressure from zero time are expressed as means
þ S.E.M. Parentheses represent the number of experiments. *, ***: Signi¢cant di¡erence against the parallel control (*P6 0.05, ***P6 0.001).
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cive to mediating the activation of NO synthase in the endo-
thelial cells. However, bradykinin B2 receptor, a well known
receptor contributing to the NO-mediated vasorelaxation, is
not involved in the ovokinin(2-7)-induced vasorelaxation be-
cause B2 antagonist HOE140 failed to block the relaxation
(Fig. 3B). Moreover, atropine (1036 M) had no e¡ect on the
dilation, indicating that this relaxation is not mediated via a
muscarinic receptor (data not shown). Further investigation is
required to identify the receptor for ovokinin(2-7).
Despite the structural similarity in its sequence to ovoki-
nin(2-7), ovokinin itself hardly induced vasorelaxation in an
isolated SHR mesenteric artery. In addition, the previous
study evidenced that ovokinin-induced vasorelaxation was
blocked by the bradykinin B1 receptor antagonist des-Arg9-
(Leu8)-bradykinin and inhibited by indomethacin but not by
L-NAME in an isolated canine mesenteric artery. These results
are quite contradictory to those shown in the present study on
ovokinin(2-7), albeit that di¡erent animal species are used.
Moreover, endogenous B1 agonist des-Arg9-bradykinin (1037
M) failed to dilate the SHR mesenteric artery, suggesting that
B1 receptors are not involved in the vasorelaxation. Given all
this, it is conceivable that ovokinin(2-7) is an obviously di¡er-
ent type of peptide from ovokinin in terms of their modes of
vasorelaxing activities. It is very interesting that these two
types of vasorelaxing peptides are released from the same
region of ovalbumin by di¡erent enzymes, i.e. chymotrypsin
and pepsin.
Orally administered ovokinin(2-7) signi¢cantly lowered the
blood pressure of SHR in a dose-dependent manner (Fig. 4B).
Most of the orally active anti-hypertensive peptides derived
from food proteins are known to be the inhibitory peptides
for angiotensin I-converting enzymes [10^15]. However, ovo-
kinin(2-7) was devoid of any inhibitory activity against these
enzymes (IC50 = s 1 mM, data not shown). Coupled with
these facts, ovokinin(2-7) exerting direct actions on endothe-
lial cells to stimulate the NO release responsible for vasodila-
tion can be regarded as the ¢rst example of such a unique
peptide derived from a natural food protein. While further
investigation remains to be conducted to verify the possibility
whether other mechanisms are involved in the ovokinin(2-7)-
induced hypotensive activity, our results indicate that vaso-
relaxing peptides derived from food proteins could play a role
as a new example of anti-hypertensive peptides.
It is noteworthy that ovokinin(2-7) showed a more potent
vasorelaxant and anti-hypertensive e¡ect in SHRs than in
WKYs. These results reinforce the concept that the receptor
for ovokinin(2-7), which is unidenti¢ed yet, might be signi¢-
cantly expressed in SHRs to compensate the hypertension.
Consequently, ovokinin(2-7) could play an important role in
the improvement of endothelial dysfunction as well as hyper-
tension.
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